Brief: Inhibikase Therapeutics Announces Pricing Of Registered Direct Offering And Warrant Inducement, Priced At-The-Market For Aggregate Gross Proceeds Of $4.0 Million
20/05/2024 14:01
May 20 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES PRICING OF REGISTERED
DIRECT
OFFERING AND WARRANT INDUCEMENT, PRICED AT-THE-MARKET FOR
AGGREGATE GROSS PROCEEDS OF $4.0 MILLION
* INHIBIKASE SETS WARRANTS EXERCISE PRICE AT $1.68
* INHIBIKASE THERAPEUTICS- ENTERED A SECURITIES PURCHASE
AGREEMENT
WITH A SINGLE INSTITUTIONAL INVESTOR TO PURCHASE 1.7 MILLION
SHARES OF COMMON STOCK
Source text for Eikon: ID:nGNXcc2WWC
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share